Luxembourg
· Delayed Price · Currency is EUR · Price in USDPharmaEssentia Company Description
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia.
The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology.
PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 1990 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 131 |
| CEO | Ko-Chung Lin |
Contact Details
Address: No. 3, Park Street Taipei, 115 Taiwan | |
| Phone | 886 2 2655 7688 |
| Website | pharmaessentia.com |
Stock Details
| Ticker Symbol | 261280558 |
| Exchange | Luxembourg Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ko-Chung Lin | Chief Executive Officer |
| Snow Chang | Chief Financial Officer |
| Samuel Lin | Chief Operating Officer |